secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROKIDNEY CORP. (PROK)
CIK:        0001850270
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0000950170-22-024799
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProKidney Q3 net loss $33.9M; cash $506.3M; Phase 3 REACT trials on track
-------------------------------------------------------------------------

- Cash and equivalents of $506.3M as of Sept 30, 2022, up from $20.6M at Dec 31, 2021, after $596.5M gross proceeds from business combination.
- Net loss before noncontrolling interest of $33.9M for Q3 2022 vs $17.1M in Q3 2021; R&D expenses $21.1M vs $14.7M.
- Phase 3 proact 1 enrolling up to 600 subjects; first interim data expected Q4 2024; proact 2 enrollment to begin Q1 2023.
- Phase 2 REGEN-007 expanded to 50 subjects; interim data expected mid-2023.
- Received UK MHRA allowance and positive EMA scientific advice for Phase 3 program supporting eventual MAA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850270/000095017022024799/0000950170-22-024799-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850270/000095017022024799/prok-20221114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024799

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer